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ABSTRACT Estrogen receptor and its ligand, estradiol,
have long been thought to be essential for survival, fertility, and
female sexual differentiation and development. Consistent with
this proposed crucial role, no human estrogen receptor gene
mutations are known, unlike the androgen receptor, where
many loss of function mutations have been found. We have
generated mutant mice lacking responsiveness to estradiol by
disrupting the estrogen receptor gene by gene targeting. Both
male and female animals survive to adulthood with normal
gross external phenotypes. Females are infertile; males have a
decreased fertility. Females have hypoplastic uteri and hyper-
emic ovaries with no detectable corpora lutea. In adult wild-
type and heterozygous females, 3-day estradiol treatment at 40
,pg/kg stimulates a 3- to 4-fold increase in uterine wet weight
and alters vaginal cornification, but the uteri and vagina do not
respond in the animals with the estrogen receptor gene dis-
ruption. Prenatal male and female reproductive tract devel-
opment can therefore occur in the absence ofestradiol receptor-
mediated responsiveness.
The estrogen receptor (ER) is a member of the steroid
receptor superfamily of ligand-activated transcription factors
(1). ER and its hormone ligand, the female sex steroid
17,B-estradiol, have long been known to play critical roles in
the development of feminine secondary sexual characteris-
tics as well as in the female reproductive cycle, infertility, and
maintenance of pregnancy. Estradiol is also thought to be
essential for embryonic and fetal development (2).
Supporting evidence for the crucial role of estrogen is
based on pharmacological and genetic data that estrogen
antagonists and inhibitors of estrogen synthesis interfere with
placental function and cause abortions (2). Overexpression
mutations in the mammalian estrogen biosynthetic enzyme,
aromatase, have been reported (3) to lead to gynecomastia in
males because of excess conversion of androgens to estro-
gens. Lack of function mutations in human placental aro-
matase have been reported to cause maternal virilization and
fetal pseudohermaphroditism in female offspring (4). This
observation suggested the need for estrogens in normal
prenatal sexual development. This interpretation may be
confounded, however, by the effects of secondarily increased
androgen concentrations. In addition, the absence of re-
ported human ER mutations supports the suggestion that if
natural ER functional mutations do occur, they may be lethal
in eutherian animals (2).
Lack of known ER mutations is contrasted with the
situation in regards to the male sex steroids, the androgens.
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Mutations in genes for the androgen receptor protein or for
androgen synthetic enzymes result in abnormalities in male
sexual differentiation and development (5-7) with little effect
in females except for a decrease in fertility (8).
The role ofestrogen action in prenatal sexual development,
however, is controversial. Endocrinological evidence for the
importance of estrogens in sexual development is found in rat
and rabbit embryogenesis studies (9, 10), where estrogen
synthesis is activated in male and female embryos at the time
ofblastocyst implantation in the uterus. Recently, ERmRNA
has been detected by the very sensitive reverse transcrip-
tase/PCR technique in blastocysts and two-cell-stage em-
bryos (11). In contrast, Jost (12), in a series of classical organ
ablation experiments, demonstrated that fetal gonadectomy
of mammalian males and females resulted in both sexes
developing as phenotypic females, suggesting that estrogen is
not needed for female sexual development. However, the
presence of maternal and placental estrogens left the question
of estrogen's importance in prenatal sexual development
unresolved.
Nevertheless, there is no doubt that estrogen plays a
central role in normal postnatal female physiology and in
female pathology, where its importance in breast and uterine
cancer, osteoporosis, and cardiovascular disease is well
known although poorly understood. Besides the normal
physiology and endocrinology of estrogen action, the mech-
anisms for hormonal stimulation have also been postulated to
involve other cellular signaling mechanisms (13-15).
Because of the various uncertainties regarding the roles of
estrogen, we decided to disrupt the ER gene in mouse
embryonic stem cells by homologous recombination, so as to
create an animal lacking a functional estrogen receptor.
Experimental development of this animal model was ex-
pected to provide a clear role for ER action in a variety of
systems under physiological conditions.
MATERIALS AND METHODS
Gene-Targeting Plasmid. The mouse ER gene has been
cloned and found to have nine exons (16). Utilizing the
published sequence and PCR (17) with oligonucleotide primer
pairs 1-2 and 3-4 (see below), we amplified two DNA
fragments from the most N-terminal exon of the mouse ER
gene. The two amplified fragments were used as probes to
allow the cloning of a 10-kb BamHI fragment containing the
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second exon of the mouse ER gene from a lambda Dash
(Stratagene) library constructed from BamHI-digested DNA
obtained from E14TG2a cells (18). To assemble the targeting
construct (Fig. 1B), a Neo gene driven by the phosphoglyc-
erate kinase (PGK) promoter and having a PGK poly(A)
addition signal (19) was cloned in a 5'-to-3' orientation in a
Not I site within exon 2 contained in a 7.5-kb BamHI/Spe I
fragment, made from the 10-kb BamHI fragment. This inser-
tion disrupts the reading frame. A flanking herpes simplex
TK gene driven by the same promoter and enhancer was
added to the 3' end of the BamHI/Spe I fragment (20).
Because of difficulty in cloning of the 5' 7-kb BamHI/Not I
fragment in plasmids, the targeting construct was assembled
in a lambda Dash bacteriophage vector. The Neo gene/Not
I/Spe I fragment and TK gene were first cloned in pBlue-
script (Stratagene) and then subcloned in a lambda Dash
vector containing the ER 7-kb BamHI/Not I fragment. A
BamHI site in the Neo gene was destroyed prior to cloning
in lambda Dash vector so that BamHI could be used to
remove the A arms.
Embryonic Stem (ES) Cells. The ES cell line E14TG2a,
derived originally from a 129/J strain mouse (18), was cul-
tured on primary embryonic fibroblast feeder layers previ-
ously irradiated with 3000 rads (30 Gy); the fibroblasts were
isolated from neomycin-resistant embryos (21) and were
resistant to G418 (Sigma).
Electroporation. Electroporation of about 1 x 107 ES cells
was in 0.5 ml of Dulbecco's modified Eagle's medium
(DMEM)/15% fetal bovine serum/0.1 mM 2-mercaptoetha-
nol/2 mM glutamine with 5 nM targeting construct with 1-sec
discharge from a 150- to 250-,uF capacitor charged to 250-400
V. In early electroporations the A arms were removed from
the targeting construct, but in later ones they were not
removed.
Selection. After electroporation, the surviving cells were
plated in 100-mm Petri dishes and exposed for 10-14 days to
G418 at 200 ,ug/ml and 1 uM ganciclovir (Syntex, Palo Alto,
CA). Colonies were picked into 24-well plates (15-mm diam-
eter wells) and grown for 10 days, when about one-tenth of
a colony was replated into a single well of the 24-well plates,
with the remainder being used to isolate DNA. DNA pre-
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FIG. 1. Diagram of the portion of the mouse ER gene targeted for
disruption. (A) Exon 2 and surrounding sequences. (B) Targeting
construct containing the neomycin resistance (Neo) and thymidine
kinase (TK) sequences. (C) Disrupted mouse ER gene after target-
ing, which inserted the Neo gene (hatched) into mouse ER exon 2
(solid black). Restriction enzyme sites: B, BamHI; H, HindIII; N,
Not I; S, Spe I. Position of the ATG start site in exon 2 is shown by
a right-angle arrow. Identity of PCR primers and their sequence
positions are shown by the numbered arrowheads corresponding to
the primers listed in Materials and Methods.
pared from these plates was pooled into groups of four and
was screened by PCR amplification to detect targeting (22).
PCR Primers. Oligo 1, used for making the 5' probe during
cloning of the ER gene: 5'-CGCTGCTGAGCCCTCT-
GCGTG-3'. Oligo 2, used for making the 5' probe during
cloning of ER gene: 5'-GTTGAACTCGTAGGCGGCGC-
CCTC-3'. Oligo 3, used for making the 3' probe during
cloning of the ER gene and for determination of the presence
of the wild-type ER gene: 5'-CGGTCTACGGCCAG-
TCGGGCACC-3'. Oligo 4, used for making the 3' probe
during cloning of the ER gene and for determination of the
presence of the wild-type ER gene: 5'-GTAGAAGGCGG-
GAGGGCCGGTGTC-3'. Oligo 5, from sequence in the 3'
end of the PGK gene, used for determination of Neo disrup-
tion of the ER gene after recombination: 5'-TTCCACATA-
CACTTCATTCTCA-3'. Oligo 6, from sequence external to
the targeting construct in intron 2 of the ER gene, used for
determination of Neo disruption of the ER gene after recom-
bination: 5'-CTCCACTGGCCTCAAACACCTG-3'.
PCR Amplification. The 3' end ofthe PGK gene, containing
the poly(A) addition signal, was sequenced. From this se-
quence, oligo 5 was designed for use in conjunction with oligo
6 to amplify a 649-bp fragment diagnostic of a successfully
targeted ER gene (see Fig. 1). For PCR screening the DNA
was from pools of four colonies of ES cells. PCR was also
used to distinguish normal, heterozygous, and homozygous
mutant animals (see Fig. 2).
Mouse Breeding. The targeted ES cells were injected into
blastocysts from C57BL/6J mothers and were returned to
pseudopregnant C57BL/6J hosts to complete their develop-
ment. Chimeras were identified by coat color and males were
bred to C57BL/6J females. Tail DNA from agouti coat color
F1 offspring was screened by PCR with primers 5 and 6 for
presence of the targeted ER gene (a 649-bp fragment). F2
offspring and subsequent generations were screened by PCR
for presence of the targeted ER gene, and with primers 3 and
4 for absence of the wild-type gene (a 239-bp fragment).
RESULTS
Gene Targeting. To make the targeting construct for inter-
rupting the reading frame of the mouse ER gene on chromo-
some 10 (23), exon 2 of the ER gene was isolated in a 10-kb
BamHI genomic DNA fragment (Fig. 1 A and B). Exon 2
contains the start codon and the N-terminal domain of the ER
gene, which is important in transcriptional control. The Neo
gene was inserted into a Not I site in this domain to disrupt
the ER reading frame. The TK gene was added to increase the
efficiency of finding targeted mouse ES cells.
Electroporation was used to introduce the targeting con-
struct into ES cells, which were then exposed to ganciclovir
and G418. About 1800 surviving colonies were screened with
primers 5 and 6 to find two in which homologous recombi-
nation had occurred as judged by the amplification of the
649-bp fragment diagnostic of targeting (Fig. 1C). Southern
blot analysis with a Neo probe confirmed that the targeted
construct was integrated at a single site (data not shown).
Generating Animals. Cells from one of these targeted ES
clones were injected into blastocysts, and four male chimeras
and four female chimeras were obtained. After several mat-
ings with different males the chimeric females showed no
germ-line transmission. Two chimeric males transmitted the
targeted gene through their germ line to produce heterozy-
gous male and female animals. Heterozygous animals were
then mated to produce homozygous animals. Fig. 2 shows the
screening profile for a representative litter from one of the
heterozygous matings. Primers 3 and 4, which bracket the
Neo integration site in the ER gene, allow detection of the
presence of the wild-type ER. PCR amplification was used to
distinguish homozygous mutants (a 649-bp band only) from
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FIG. 2. PCR analysis of a representative litter from a mating of
heterozygotes. Even-numbered lanes represent PCRs using primer
sets 5 and 6, and odd-numbered lanes used primer sets 3 and 4.
Heterozygote parents are shown in the upper gel, and male (o) and
female (o) offspring are depicted in the lower gel. Two PCR assays
have been employed in the genotyping of the mice. Primers 3 and 4
amplify a 239-bp product specific for the wild-type ER gene, and
primers 5 and 6 amplify a 649-bp product specific for the disrupted
gene.
heterozygotes (a 649-bp and a 239-bp band) and from normal
animals (only the 239-bp band). PCR products were further
characterized by restriction enzymes: the nontargeted band
(239 bp) was cut by Not I, producing two bands of expected
size 43 and 186 bp. As expected, the targeted 649-bp PCR ER
product was not cut with Not I; subsequent nucleotide
sequencing showed that the targeted fragment contained the
predicted sequence.
Breeding Data. A total of 48 heterozygous matings have
been performed, generating 361 offspring with a normal
average litter size of 8 pups. The genotype frequencies are
shown in Table 1. There was no apparent gender preference,
since almost equal numbers of male and female progeny were
produced throughout all three genotype groups. Relative
birth frequency of homozygous mutant animals (ER-
disrupted) is slightly lower than expected for a Mendelian
distribution and is less than that found in the wild-type group.
However, statistical analysis using a x2 goodness-of-fit test
indicated that the deviation from expectation was not signif-
icant (P = 0.07).
Phenotype of the Animals. The external phenotypes of
animals of both sexes that are homozygous for the disrupted
Table 1. Frequency of pup genotypes from heterozygous matings
W WM M Total
Males 56 (15) 95 (26) 31 (9) 182 (50)
Females 54 (15) 86 (24) 39 (11) 179 (50)
Total 99 (30) 181 (50) 70 (20) 361 (100)
Numbers of offspring from a total of 48 heterozygous matings are
reported for each group: wild-type ER (W), heterozygote (WM), and
homozygous mutant ER (M). Numbers in parentheses are the
percentage of offspring in each group. x2 goodness-of-fit test indi-
cated that the deviation from Mendelian ratio was not significant (P
= 0.07).
gene were normal. Internally only the females showed no-
ticeable gross differences from normal, with hypoplastic uteri
as well as ovaries that lacked corpora lutea (see Fig. 4).
Histologically, the uteri and hyperemic cystic ovaries were
abnormal. Fig. 3A shows a histological section of an ovary
from a wild-type animal. Primary follicles can be seen, with
examples of preantral tertiary follicles and corpora lutea
present in the section. In contrast, ovaries from the homozy-
gous mutant animals show classic cystic and hemorrhagic
follicles containing few if any granulosa cells (Fig. 3B). A few
primary follicles can be seen, but no corpora lutea were
observed in these ovaries. The histology of the uterus showed
the presence of all major uterine cell types, but the stromal,
epithelial, and myometrial tissue compartments were present
in diminished size. Uterine glands were present as well as
ciliated epithelial cells in the oviduct (data not presented).
Males appear overtly normal, but testis weight was low
compared with wild-type or heterozygote animals. On the
other hand, seminal vesicle and coagulating gland weights
were not significantly different. Sperm were present in the
testis and epididymus, but the sperm count was low, only
10% of the control level. Functionality and motility of the
sperm from the recessive males are not yet known.
Responses to Estrogen. To test for estrogen responsiveness,
adult females were treated for 3 days with estradiol at levels
known to increase uterine wet weight, induce hyperemia, and
alter vaginal epithelial cytology in normal animals (24). The
wild-type and heterozygous animals responded normally
compared with untreated controls (Fig. 4A) by an increase in
uterine wet weight of 3- to 4-fold (Fig. 4B). The uteri from
wild type (Fig. 4B) and heterozygotes (data not presented)
became hyperemic after a 3-day bioassay. The uteri of the
homozygous ER-disrupted animals did not respond with
either an increase in uterine weight wet or hyperemia (Fig. 4
C and D). Unlike wild-type and heterozygous animals, ER-
disrupted animals treated with estradiol for 4-6 hr showed no
uterine water imbibition or uterine hyperemia (data not
presented). Vaginal cytology after estradiol treatment
showed an increased number of cornified epithelial cells in
the wild-type and heterozygous animals but was unaltered in
ER-disrupted animals (data not shown).
Estrogen Binding. Ligand-binding analyses of uterine tis-
sue from the ER-disrupted animals showed detectable estra-
diol binding (25) at about 5% of the wild-type level (60-70
fmol/100 ,ug of DNA), with a dissociation constant similar to
that of the wild type (0.7 nM). Low concentrations of ER
protein were confirmed by an ELISA (Abbott) using two
antibodies to the C terminus of the ER protein. "Splicing
over" of insertional mutations (26) or nonsense codons (27)
has been observed previously. In vivo reinitiation of trans-
lation after a nonsense mutation, resulting in a ligand-
nonresponsive receptor protein, has also been seen previ-
ously in the steroid receptor superfamily (28).
Fertility. All homozygous mutant females are infertile.
None showed any lordosis posture or receptiveness to wild-
type males even when treated with estrogen. This behavior
suggests absence of estrogen responsiveness in the central
nervous system. Male fertility was tested with harem pairings
to known fertile wild-type females. Fertility was reduced, but
not abolished, since only 3 of 15 paired males produced any
offspring. However, the males that initially demonstrated
fertility have not to date sired any more litters after several
pairings. No vaginal plugs were found in any of the matings
of both sexes of homozygous mutant animals, with the
exception of the 3 fertile males.
DISCUSSION
The homozygous mutant mice with ER-disrupted genes ap-
pear healthy, and with the exception of fertility problems in
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FIG. 3. Histology of mouse ovaries from untreated animals stained with hematoxylin and eosin. (A) Control wild type. (x22.) (B)
ER-disrupted homozygous mutant mice. (x45.)
both male and female animals, there are no obvious problems
in prenatal sexual development. This is surprising because of
the known importance of estrogens in breast and uterine
growth and because oftheir effects on cardiovascular disease
and in preventing bone loss after menopause and after
ovariectomy in mice. Possibly there is a parallel regulatory
pathway that can make up for the lack of estrogen respon-
siveness during prenatal sexual differentiation and develop-
ment. It is also possible (see below) that some residual
functions are retained by the disrupted gene, but in either
case, these alternate pathways do not enable the uterus or
vagina to respond to estradiol. Growth factors, such as
insulin-like growth factor 1, epidermal growth factor, and
transforming growth factor a, may be involved in possible
alternative regulatory pathways, since they have been linked
to estrogen action in uterine tissue (14, 15, 29).
Other members of the steroid receptor superfamily have
been targeted by homologous recombination. In some iso-
forms of the retinoic acid receptor (RAR) family the gene
disruptions have resulted in alterations in phenotype while in
others they have not (30-32). Disruption of one N-terminal
exon of the RARa-1 and RARy-2 isoforms resulted in a
normal phenotype, while disruption of a different N-terminal
exon of the RARa and RARygenes produced early postnatal
lethality.
Traditional pronuclear injection transgenic techniques
which produce overexpression of the ER result in aberrant
reproductive phenotypes with alterations in the length of
parturition.tt However, as in our ER-disrupted animals, no
abnormalities in prenatal sexual development are seen, al-
though at the neuroendocrine, end organ, and gonadal level,
reproductive function appears to be severely compromised.
The observation of apparently normal development of pre-
natal sexual phenotypes, associated with fertility problems,
suggests that ER defects may be responsible for some human
infertility problems. It will now be interesting to see if any
human male or female infertilities might be caused by ER
mutations or in genes regulated by ER. Past reports have
suggested silent ER codon polymorphisms may be linked
ttDavis, V. L., Couse, J. F., Goulding, E. H., Eddy, E. M. &
Korach, K. S., Proceedings of the American Association for
Cancer Research, Mechanism of Action of Retinoids, Vitamin D,
and Steroid Hormones, C10, 1993, Banff, Canada.
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FIG. 4. Uteri from wild-type (A and B) and
ER-disrupted homozygous mutant (C and D) mice
after treating daily for 3 days with a 100-1. s.c.
injection of propylene glycol vehicle (A and C) or a
40-,ug/kg dose of estradiol in the same vehicle (B
and D). (xl.) Uteri were removed, and the follow-
ing data are expressed as the ratio of uterine wet
weight (mg) to body weight (g). (A) Control wild
type given propylene glycol (1.0). (B) Wild type
given estradiol (3.8). (C) Homozygous mutant given
propylene glycol (0.8). (D) Homozygous mutant
given estradiol (0.7). Results are representative of
four separate experiments.
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with hypertension (34) and spontaneous abortions as well as
increased susceptibility to breast cancer (35), but to date
there have been no reports of ER changes in relation to
fertility. Further studies into the susceptibility of the ER-
disrupted mice to hypertension and mammary gland cancer
will be valuable in assessing nonestrogenic risk factors.
Assessment of bone strength, cardiovascular disease suscep-
tibility, and atherosclerosis during aging will also help us
learn more about the roles played by the ER in these
pathophysiologies.
Our observation that we can still detect about 5% of normal
estradiol binding in uterine preparations from animals ho-
mozygous for the gene disruption and demonstrably unre-
sponsive to estradiol is especially interesting. The binding has
the same affinity as determined for normal estrogen receptor.
While the gene disruption that we have constructed abolished
estrogen responsiveness, it is possible that a protein product
able to bind estrogen may still be generated; for example a
"splicing over" event may have occurred that eliminated
exon 2. Examples are known of exons being "spliced over"
when a nonsense codon is found in an exon (27) or when Neo
has been inserted into the exon by targeting (26). Examples
of mutant ER isoforms lacking different exons have been
identified by mRNA analysis from primary tumors or cancer
cell lines (36). A recent report has shown in normal rat brain
tissue an ER isoform lacking exon 4 (37); however this
protein would not be capable of binding ligand. An altered
form of the normal receptor may be synthesized after the ER
gene disruption. If so, it is incapable of mediating estrogen
responsiveness, either because of its structure or because it
is synthesized at too low a level. We have shown earlier that
uterine responsiveness to estrogen does not occur in mice if
receptor levels are decreased to below 20% of control (38).
Interestingly, the testicular feminization mouse (39) does
not respond to androgen because of a frameshift mutation in
the androgen receptor N-terminal domain. Low levels of
androgen receptor binding are detectable. Reinitiation of
translation downstream of the nonsense codon is believed to
occur, such that the C-terminal ligand-binding domain is
present in very low amounts without the N-terminal domain
(28). It is tempting to speculate that something similar may be
happening with our ER-disrupted mice.
Alternatively, the ER form detected by binding in the
homozygous mutant animals may represent another, previ-
ously undetected, estrogen-binding protein. Further studies
will be needed to characterize the molecular nature and
possible function of the residual estrogen binding activity in
our homozygous mutant mice.
In any case, the homozygous mutants with the ER-
disrupted genes are not physiologically responsive to estro-
gens by several classical bioassays of estrogenic activity-
increase in uterine water imbibition, stimulation of uterine
hyperemia, and change in vaginal cornification. Detection of
ER early in development (11) and the apparent role of
estrogen in blastocyst activation (9, 10, 33) make it remark-
able that prenatal sexual development is not altered and that
lethality did not occur in the animals with their ER genes
disrupted.
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